+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases



Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases



Diabetes Care 35(6): E40




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056007364

Download citation: RISBibTeXText

PMID: 22619292

DOI: 10.2337/dc12-0163


Related references

The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy. Journal of Clinical Endocrinology and Metabolism 95(8): 3599-3604, 2010

Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy. European Journal of Pediatrics 168(3): 359-361, 2008

Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control. Diabetic Medicine 35(3): 386-391, 2017

Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report. Diabetes Research and Clinical Practice 100(1): E1-E2, 2014

Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea. Archives of Endocrinology and Metabolism 59(6): 559-561, 2016

Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene. Arquivos Brasileiros de Endocrinologia E Metabologia 54(8): 682-684, 2011

Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation. Diabetes Research and Clinical Practice 91(1): E1-E3, 2011

Long-term response to sulfonylurea in a patient with diabetes due to mutation in the Kcnj11 gene. Arquivos Brasileiros de Endocrinologia & Metabologia 54(8): 682-684, 2010

Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel KCNJ11 mutation. Korean Journal of Pediatrics 58(8): 309-312, 2015

Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation. Pediatric Diabetes 11(4): 286-288, 2012

Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in KCNJ11. Annals of Pediatric Endocrinology and Metabolism 23(3): 154-157, 2018

The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. Journal of Clinical Endocrinology and Metabolism 93(3): 1054-1061, 2007

An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes 56(2): 328-336, 2007

Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation. Diabetes Research and Clinical Practice 108(1): E18-E20, 2015

Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation. Hormone and Metabolic Research 41(7): 580-582, 2009